Phaseline

Targets › MAP2K1

MAP2K1 (Dual specificity mitogen-activated protein kinase kinase 1): drug programs, companies and trials

26 programs from 25 companies in 241 trials: 121 Phase 2, 72 Phase 1, 25 Phase 4, 23 Phase 3; Oncology, Other, Cardiovascular; next expected readout Nov 2026.

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. (UniProt, Q02750)

Open in Phaseline: the race on MAP2K1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisTrametinib
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
MAP2K2, MAP2K1Phase 4Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); EGFR-mutant Non-small Cell Lung Cancer …Nov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
PfizerBinimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 4Solid Tumors; MelanomaJul 2029
Pierre Fabre MedicamentBinimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Melanoma; Non-Small Cell Lung Cancer; Solid Tumor, Adult; Solid Tumor …Dec 2026
Verastemavutometinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation …Dec 2026
Shanghai Kechow Pharmatunlametinib
MEK1/2 inhibitor
MAP2K1, MAP2K2Phase 3Colorectal Cancer Metastatic; Melanoma; Melanoma Advanced; Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation …Dec 2026
AstraZenecaSelumetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV; Neurofibromatosis 1; Advanced Non Small Cell Lung Cancer; Tumor …Dec 2026
Chia Tai Tianqing Pharmaceutical GroupTQ-B3234 capsules
Selective MEK1/2 inhibitor
MAP2K1, MAP2K2Phase 3Plexiform NeurofibromaDec 2027
Shanghai JMT-BioGlumetinib
MEK inhibitor
MAP2K1Phase 3Non-Small Cell Lung CancerFeb 2028
ImmuneeringAtebimetinib
MEK inhibitor
MAP2K1Phase 3Pancreatic CancerJun 2028
RocheCobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Non-small Cell Lung Cancer; Melanoma; Metastatic Distal Bile Duct Adenocarcinoma; Chronic Myelomonocytic Leukemia (CMML) …Nov 2026
CSPC ZhongQi Pharmaceutical TechnologyGlumetinib
MEK inhibitor
MAP2K1Phase 2Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsApr 2027
RocheCobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Non-Small Cell Lung Cancer; Ovarian CancerJun 2027
Peng ZhangFumetinib combined platinum-based double chemotherapy
MEK inhibitor
MAP2K1Phase 2EGFRNov 2027
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyMirdametinib (PD-0325901)
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Plexiform Neurofibroma; Healthy; Slow-Flow Vascular Malformation; Advanced Unresectable Melanoma …Dec 2028
Shanghai Fosun Pharmaceutical Industrial Developmentluvometinib
MEK1/2 inhibitor
MAP2K1Phase 2Non-small Cell Lung CanerJun 2029
Hanmi Pharmaceutical CompanyCobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Advanced or Metastatic MelanomaSep 2029
University of Alabama at BirminghamZEN-3694
MEK inhibitor
MAP2K1Phase 2MPNSTNov 2031
Merck KGaAMirdametinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 1HealthyNov 2026
Recursion PharmaceuticalsTak-733 (REC-4881)
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 1Familial Adenomatous PolyposisJun 2027
Washington University School of MedicineZunsemetinib
MEK inhibitor
MAP2K1Phase 1Metastatic Pancreatic Ductal Adenocarcinoma; Hormone Receptor Positive HER-2 Negative Metastatic Breast CancerJun 2027
Pasithea TherapeuticsPAS-004
MEK 1/2 inhibitor
MAP2K1, MAP2K2Phase 1RAS Mutation; NF1 MutationSep 2027
GenfitGNS561
MEK inhibitor
MAP2K1Phase 1CholangiocarcinomaDec 2027
Nested TherapeuticsNST-628
non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway
RAF1, MAP2K1Phase 1OncologyNov 2028
Liu HuangGlumetinib
MEK inhibitor
MAP2K1Phase 1Metastatic Colorectal CancerDec 2028
Haihe BiopharmaGlumetinib
MEK inhibitor
MAP2K1Phase 1C-Met Exon 14 Mutation–

Conditions

Melanoma (8) Advanced Lymphoma (6) Neurofibromatosis 1 (5) Non-Small Cell Lung Cancer (4) Neurofibromatosis Type 1 (3) Low Grade Glioma (3) Non-small Cell Lung Cancer (3) Metastatic Malignant Neoplasm in the Brain (3) Nicotine Dependence (3) MPNST (2) Metastatic Melanoma (2) Solid Tumor, Adult (2)

Modalities

small molecule (18), mixed (5), antibody (1), protein or peptide (1)

Companies

Roche (2) University of Alabama at Birmingham (1) AstraZeneca (1) Pierre Fabre Medicament (1) Shanghai Kechow Pharma (1) Pasithea Therapeutics (1) Genfit (1) Novartis (1) Merck KGaA (1) SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) University of California, San Francisco (1) Nested Therapeutics (1) Verastem (1) Peng Zhang (1) Immuneering (1) Washington University School of Medicine (1) Pfizer (1) Chia Tai Tianqing Pharmaceutical Group (1) CSPC ZhongQi Pharmaceutical Technology (1) Haihe Biopharma (1)

Related targets

MAP2K2 (15) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MS4A1 (1) CHRM3 (1) CHRM2 (1) ADRB3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.